Management of mycosis fungoides: Part 2. Treatment

ONCOLOGY

Volumn 17, Issue 10, 2003, Pages 1419-1428

  Smith, Benjamin D ^a   Wilson, Lynn D ^b  

^a Therapeutic Radiology

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID;

BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; HUMAN; MYCOSIS FUNGOIDES; PHOTOTHERAPY; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; HUMANS; MYCOSIS FUNGOIDES; PHOTOTHERAPY;

EID: 1542673196     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Esteve E, Bagot M, Joly P, et al: A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol 135:1349-1353, 1999.
2. Kim YH, Martinez G, Varghese A, et al: Topical nitrogen mustard in the management of mycosis fungoides: Update of the Stanford experience. Arch Dermatol 139:165-173, 2003.
3. Licata AG, Wilson LD, Braverman IM, et al: Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. Arch Dermatol 131:432-435, 1995.
4. Zackheim HS, Epstein EH Jr, Crain WR: Topical carmustine (BCNU) for cutaneous T cell lymphoma: A 15-year experience in 143 patients. J Am Acad Dermatol 22:802-810, 1990.
5. Zackheim HS, Kashani-Sabet M, Amin S: Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 134:949-954, 1998.
6. Talpur R, Ward S, Apisamthanarax N, et al: Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 47:672-684, 2002.
7. Breneman D, Duvic M, Kuzel T, et al: Phase 1 and 2 trial of bexarotene gel for skin- directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 138:325-332, 2002.
8. Edelson R, Berger C, Gasparro F, et al: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316:297-303, 1987.
9. British Photodermatology Group guidelines for PUVA. Br J Dermatol 130:246-255, 1994.
10. Abel EA, Sendagorta E, Hoppe RT, et al: PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study. Arch Dermatol 123:897-901, 1987.
11. Ramsay DL, Lish KM, Yalowitz CB, et al: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128:931-933, 1992.
12. Diederen PV, van Weelden H, Sanders CJ, et al: Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: A retrospective study. J Am Acad Dermatol 48:215-219, 2003.
13. Gathers RC, Scherschun L, Malick F, et al: Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol 47:191-197, 2002.
14. Young AR: Carcinogenicity of UVB phototherapy assessed. Lancet 345:1431-1432, 1995.
15. Jones GW, Kacinski BM, Wilson LD, et al: Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 47:364-370, 2002.
16. Ross C, Tingsgaard P, Jorgensen H, et al: Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 51:63-72, 1993.
17. Jumbou O, N'Guyen JM, Tessier MH, et al: Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 140:427-431, 1999.
18. Roenigk HH Jr, Kuzel TM, Skoutelis AP, et al: Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95:198S-205S, 1990.
19. Kuzel TM, Roenigk HH Jr, Samuelson E, et al: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 13:257-263, 1995.
20. Chiarion-Sileni V, Bononi A, Fomasa CV, et al: Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Canter 95:569-575, 2002.
21. Wollina U, Looks A, Meyer J, et al: Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: A prospective controlled trial. J Am Acad Dermatol 44:253-260, 2001.
22. Foss FM, Hide DC, Linnoila IR, et al: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fun- goides/Sezary syndrome. J Clin Oncol 12:2051-2059, 1994.
23. Foss FM, Ihde DC, Breneman DL, et al: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 10:1907-1913, 1992.
24. Stadler R, Otte HG, Luger T, et al: Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 92:3578-3581, 1998.
25. Kuzel TM, Gilyon K, Springer E, et al: Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82:203-207, 1990.
26. Thomsen K, Hammar H, Molin L, et al: Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 69:536-538, 1989.
27. Kim YH, Hoppe RT: Mycosis fungoides and the Sezary syndrome. Semin Oncol 26:276-289, 1999.
28. Duvic M, Hymes K, Heald P, et al: Bexarotene is effective and safe for treatment of refr actory advanced- stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 19:2456-2471, 2001.
29. Duvic M, Martin AG, Kim Y, et al: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137:581-593, 2001.
30. Olsen E, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutane- ous T-cell lymphoma. J Clin Oncol 19:376-388, 2001.
31. Lim HW, Edelson RL: Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1117-1126, 1995.
32. Berger CL, Hanlon D, Kanada D, et al: Transimmunization, a novel approach for tumor immunotherapy. Transfits Apheresis Sci 26:205-216, 2002.
33. Heald P, Rook A, Perez M, et al: Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemo- therapy. J Am Acad Dermatol 27:427-433, 1992.
34. Kuzel TM, Hurria A, Samuelson E, et al: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87:906-911, 1996.
35. Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am 9:1109-1116, 1995.
36. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 42:40-46, 2000.
37. Zackheim HS, Kashani-Sabet M, Hwang ST: Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patients. J Am Acad Dermatol 34:626-631, 1996.
38. Zinzani PL, Baliva G, Magagnoli M, et al: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18:2603-2606, 2000.
39. Sarris AH, Phan A, Duvic M, et al: Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol 20:2876-2880, 2002.
40. Bigler RD, Crilley P, Micaily B, et al: Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 7:133-137, 1991.
41. Russell-Jones R, Child F, Olavarria E, et al: Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: Predictors of disease-free survival. Ann N Y Acad Sci 941:147-154, 2001.
42. Sterling JC, Marcus R, Burrows NP, et al: Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 20:73-75, 1995.
43. Guitart J, Wickless SC, Oyama Y, et al: Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 138:1359-1365, 2002.
44. Masood N, Russell KJ, Olerud JE, et al: Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 47:140-145, 2002.
45. Burt RK, Guitart J, Traynor A, et al: Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 25:111-113, 2000.
46. Kaye FJ, Bunn PA, Jr., Steinberg SM, et al: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321:1784-1790, 1989.
47. Heald PW, Glusac EJ: Unilesional cutaneous T-cell lymphoma: Clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant. J Am Acad Dermatol 42:283-285, 2000.
48. Wilson LD, Kacinski BM, Jones GW: Local superficial radiotherapy in the management of minimal stage 1A cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 40:109-115, 1998.
49. Micaily B, Miyamoto C, Kantor G, et al: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42:361-364, 1998.
50. Kim YH, Jensen RA, Watanabe GL, et al: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132:1309-1313, 1996.
51. Herrmann JJ, Roenigk HH Jr, Hurria A, et al: Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up. J Am Acad Dermatol 33:234-242, 1995.
52. Honigsmann H, Brenner W, Rauschmei- er W, et al: Photochemotherapy for cutaneous T cell lymphoma. A follow-up study. J Am Acad Dermatol 10:238-245, 1984.
53. Chinn DM, Chow S, Kim YH, et al: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43:951-958, 1999.
54. Quiros PA, Jones GW, Kacinski BM, et al: Total skin electron beam therapy followed by adjuvant psoralen/ultravioIet-A light in the management of patients with Tl and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38:1027-1035, 1997.
55. Becker M, Hoppe RT, Knox SJ: Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 32:1445-1449, 1995.
56. Wilson LD, Quiros PA, Kolenik SA, et al: Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 35:69-73, 1996.
57. Jones GW, Hoppe RT, Glatstein E: Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1057-1076, 1995.
58. Wilson LD, Licata AL, Braverman IM, et al: Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 32:987-995, 1995.
59. Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer 85:1985-1995, 1999.
60. Wilson LD, Jones GW, Kim D, et al: Experience with total skin electron beam therapy in combination with extracorporeal pho- topheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 43:54-60, 2000.
61. Scarisbrick JJ, Child FJ, Clift A, et al: A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 144:1010-1015, 2001.
62. Greiner D, Olsen EA, Petroni G: Pen- tostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 36:950-955, 1997.
63. Bunn PA, Jr., Hoffman SJ, Norris D, et al: Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 121:592-602, 1994.
64. de Coninck EC, Kim YH, Varghese A, et al: Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 19:779-784, 2001.
65. Axelrod PI, Lorber B, Vonderheid EC: Infections complicating mycosis fungoides and Sezary syndrome. JAMA 267:1354-1358, 1992.
66. Apisiarnthanarax N, Talpur R, Duvic M: Treatment of cutaneous T cell lymphoma: Current status and future directions. Am J Clin Dermatol 3:193-215, 2002.